NSG 5240 Advanced Pharmacology Final Exam |
2026/2027 Edition | 50 Questions with Evidence-Based
Verified Answers
Advanced Pharmacology | Expert-Aligned Q&A | Certification-Ready Format
Introduction
This 50-question original competency assessment focuses on advanced pharmacology domains, emphasizing
pharmacokinetic and pharmacodynamic principles, evidence-based drug therapy, medication safety, therapeutic
monitoring, and management of acute and chronic conditions across diverse patient populations. Items integrate
absorption, distribution, metabolism, excretion, receptor activity, drug classifications, renal and hepatic considerations,
interaction risk, antimicrobial stewardship, controlled substance safety, and individualized therapy to support optimal
therapeutic outcomes.
Content Area Overview: 50 Questions
Content Area Questions Key Topics Weight
Pharmacokinetics, Absorption, distribution,
Pharmacodynamics, and 10 metabolism, excretion, half-life, 20%
Prescriber Principles clearance, receptors, dose selection
Autonomic, Central Nervous Adrenergic drugs, anticholinergics,
System, and Pain Management 10 antidepressants, seizure therapy, 20%
Pharmacology opioids, pain safety
Hypertension, heart failure,
Cardiovascular, Renal, and
13 anticoagulants, lipids, thyroid, 25%
Endocrine System Pharmacology
diabetes, renal dosing
Antibiotic stewardship, antivirals,
Anti-infective, Immune, and
10 antifungals, corticosteroids, 20%
Inflammatory Pharmacology
immunomodulators, toxicity
Older adults, pregnancy, lactation,
Prescriber Safety, Ethics, and pediatrics, cost, controlled
7 15%
Special Populations substances, medication
reconciliation
Examination Questions
Domain: Pharmacokinetics, Pharmacodynamics, and Prescriber Principles
1. A patient with chronic kidney disease is prescribed a medication primarily eliminated unchanged in
the urine. Which action is most appropriate?
A. Give the usual adult dose without adjustment
B. Adjust dose or interval based on renal function and therapeutic need
C. Double the dose to overcome renal impairment
D. Stop all medications metabolized by the liver
Correct Answer: B. Adjust dose or interval based on renal function and therapeutic need
Rationale: Reduced renal clearance increases drug exposure and toxicity risk, so dosage individualization is required.
2. Which pharmacokinetic parameter best determines a loading dose?
A. Half-life only
B. Clearance only
C. Protein binding only
D. Volume of distribution
Correct Answer: D. Volume of distribution
Rationale: Loading dose is based on target concentration and volume of distribution, because it estimates the amount needed to
fill body compartments.
, 3. Which pharmacokinetic parameter most directly determines maintenance dosing rate?
A. Tablet color
B. Clearance
C. Route label only
D. Receptor selectivity only
Correct Answer: B. Clearance
Rationale: Maintenance dosing replaces drug eliminated over time, making clearance the key determinant of dosing rate.
4. A medication has a narrow therapeutic index. What is the safest management approach?
A. Use the largest available dose
B. Avoid patient education
C. Assume toxicity cannot occur
D. Monitor serum levels or clinical markers closely when indicated
Correct Answer: D. Monitor serum levels or clinical markers closely when indicated
Rationale: Narrow therapeutic index drugs have small margins between benefit and toxicity and require closer monitoring.
5. Which statement best describes first-pass metabolism?
A. Drug bypasses the liver after oral dosing
B. Drug is metabolized in the gut wall or liver before reaching systemic circulation
C. Drug is excreted unchanged by the lungs
D. Drug binds receptors irreversibly in every case
Correct Answer: B. Drug is metabolized in the gut wall or liver before reaching systemic circulation
Rationale: First-pass metabolism can reduce oral bioavailability and influence dose and route selection.
6. A medication reaches steady state after repeated dosing. Which factor primarily determines the time
to steady state?
A. Pill shape
B. Patient height alone
C. Package insert length
D. Half-life
Correct Answer: D. Half-life
Rationale: Most drugs approach steady state after about four to five half-lives, regardless of dose size.
7. Which term describes the relationship between drug concentration and clinical effect?
A. Pharmacoeconomics only
B. Pharmacodynamics
C. Bioequivalence only
D. Medication reconciliation
Correct Answer: B. Pharmacodynamics
Rationale: Pharmacodynamics evaluates what the drug does to the body, including receptor effects and dose-response
relationships.
8. A drug is a partial agonist. Which statement is correct?
A. It has no receptor activity
B. It always causes permanent receptor damage
C. It blocks all drug absorption
D. It activates receptors but produces a lower maximal effect than a full agonist
Correct Answer: D. It activates receptors but produces a lower maximal effect than a full agonist
Rationale: Partial agonists have intrinsic activity but cannot produce the full receptor-mediated response.
9. Which situation most increases free active drug concentration for a highly protein-bound
medication?
A. Improved tablet coating
B. Hypoalbuminemia or displacement from binding sites
C. Taking the drug with water
D. Changing pharmacy location
Correct Answer: B. Hypoalbuminemia or displacement from binding sites
Rationale: Lower albumin or displacement can increase unbound drug, raising pharmacologic and toxicity risk.
10. A prescriber selects a medication after considering efficacy, safety, cost, patient preference, and
monitoring needs. Which principle is being applied?
A. Random product selection
2026/2027 Edition | 50 Questions with Evidence-Based
Verified Answers
Advanced Pharmacology | Expert-Aligned Q&A | Certification-Ready Format
Introduction
This 50-question original competency assessment focuses on advanced pharmacology domains, emphasizing
pharmacokinetic and pharmacodynamic principles, evidence-based drug therapy, medication safety, therapeutic
monitoring, and management of acute and chronic conditions across diverse patient populations. Items integrate
absorption, distribution, metabolism, excretion, receptor activity, drug classifications, renal and hepatic considerations,
interaction risk, antimicrobial stewardship, controlled substance safety, and individualized therapy to support optimal
therapeutic outcomes.
Content Area Overview: 50 Questions
Content Area Questions Key Topics Weight
Pharmacokinetics, Absorption, distribution,
Pharmacodynamics, and 10 metabolism, excretion, half-life, 20%
Prescriber Principles clearance, receptors, dose selection
Autonomic, Central Nervous Adrenergic drugs, anticholinergics,
System, and Pain Management 10 antidepressants, seizure therapy, 20%
Pharmacology opioids, pain safety
Hypertension, heart failure,
Cardiovascular, Renal, and
13 anticoagulants, lipids, thyroid, 25%
Endocrine System Pharmacology
diabetes, renal dosing
Antibiotic stewardship, antivirals,
Anti-infective, Immune, and
10 antifungals, corticosteroids, 20%
Inflammatory Pharmacology
immunomodulators, toxicity
Older adults, pregnancy, lactation,
Prescriber Safety, Ethics, and pediatrics, cost, controlled
7 15%
Special Populations substances, medication
reconciliation
Examination Questions
Domain: Pharmacokinetics, Pharmacodynamics, and Prescriber Principles
1. A patient with chronic kidney disease is prescribed a medication primarily eliminated unchanged in
the urine. Which action is most appropriate?
A. Give the usual adult dose without adjustment
B. Adjust dose or interval based on renal function and therapeutic need
C. Double the dose to overcome renal impairment
D. Stop all medications metabolized by the liver
Correct Answer: B. Adjust dose or interval based on renal function and therapeutic need
Rationale: Reduced renal clearance increases drug exposure and toxicity risk, so dosage individualization is required.
2. Which pharmacokinetic parameter best determines a loading dose?
A. Half-life only
B. Clearance only
C. Protein binding only
D. Volume of distribution
Correct Answer: D. Volume of distribution
Rationale: Loading dose is based on target concentration and volume of distribution, because it estimates the amount needed to
fill body compartments.
, 3. Which pharmacokinetic parameter most directly determines maintenance dosing rate?
A. Tablet color
B. Clearance
C. Route label only
D. Receptor selectivity only
Correct Answer: B. Clearance
Rationale: Maintenance dosing replaces drug eliminated over time, making clearance the key determinant of dosing rate.
4. A medication has a narrow therapeutic index. What is the safest management approach?
A. Use the largest available dose
B. Avoid patient education
C. Assume toxicity cannot occur
D. Monitor serum levels or clinical markers closely when indicated
Correct Answer: D. Monitor serum levels or clinical markers closely when indicated
Rationale: Narrow therapeutic index drugs have small margins between benefit and toxicity and require closer monitoring.
5. Which statement best describes first-pass metabolism?
A. Drug bypasses the liver after oral dosing
B. Drug is metabolized in the gut wall or liver before reaching systemic circulation
C. Drug is excreted unchanged by the lungs
D. Drug binds receptors irreversibly in every case
Correct Answer: B. Drug is metabolized in the gut wall or liver before reaching systemic circulation
Rationale: First-pass metabolism can reduce oral bioavailability and influence dose and route selection.
6. A medication reaches steady state after repeated dosing. Which factor primarily determines the time
to steady state?
A. Pill shape
B. Patient height alone
C. Package insert length
D. Half-life
Correct Answer: D. Half-life
Rationale: Most drugs approach steady state after about four to five half-lives, regardless of dose size.
7. Which term describes the relationship between drug concentration and clinical effect?
A. Pharmacoeconomics only
B. Pharmacodynamics
C. Bioequivalence only
D. Medication reconciliation
Correct Answer: B. Pharmacodynamics
Rationale: Pharmacodynamics evaluates what the drug does to the body, including receptor effects and dose-response
relationships.
8. A drug is a partial agonist. Which statement is correct?
A. It has no receptor activity
B. It always causes permanent receptor damage
C. It blocks all drug absorption
D. It activates receptors but produces a lower maximal effect than a full agonist
Correct Answer: D. It activates receptors but produces a lower maximal effect than a full agonist
Rationale: Partial agonists have intrinsic activity but cannot produce the full receptor-mediated response.
9. Which situation most increases free active drug concentration for a highly protein-bound
medication?
A. Improved tablet coating
B. Hypoalbuminemia or displacement from binding sites
C. Taking the drug with water
D. Changing pharmacy location
Correct Answer: B. Hypoalbuminemia or displacement from binding sites
Rationale: Lower albumin or displacement can increase unbound drug, raising pharmacologic and toxicity risk.
10. A prescriber selects a medication after considering efficacy, safety, cost, patient preference, and
monitoring needs. Which principle is being applied?
A. Random product selection
